

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 02 STN pricing information for 2008 now available
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5 JAN 28 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra
NEWS 16 MAR 31 CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements
NEWS 23 MAY 30 INPAFAMDB now available on STN for patent family searching
NEWS 24 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 25 JUN 06 EPFULL enhanced with 260,000 English abstracts
NEWS 26 JUN 06 KOREAPAT updated with 41,000 documents
NEWS 27 JUN 13 USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 28 JUN 19 CAS REGISTRY includes selected substances from web-based collections
NEWS 29 JUN 25 CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 30 JUN 30 AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 31 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated

NEWS 32 JUN 30 organizations
STN on the Web enhanced with new STN AnaVist
Assistant and BLAST plug-in
NEWS 33 JUN 30 STN AnaVist enhanced with database content from EPFULL

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus *

FILE 'HOME' ENTERED AT 08:59:51 ON 07 JUL 2008

FILE 'REGISTRY' ENTERED AT 09:00:16 ON 07 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 JUL 2008 HIGHEST RN 1032827-24-9
DICTIONARY FILE UPDATES: 6 JUL 2008 HIGHEST RN 1032827-24-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> E "EPOTHILONE B"/CN 25
E1 1 EPOTHILONE A8/CN
E2 1 EPOTHILONE A9/CN
E3 1 --> EPOTHILONE B/CN
E4 1 EPOTHILONE B (12R,13R) ACETONIDE/CN
E5 1 EPOTHILONE B A-EPOXIDE/CN
E6 1 EPOTHILONE B ACID/CN

E7 1 EPOTHILONE B HYDROXYLASE/CN
E8 1 EPOTHILONE B HYDROXYLASE (AMYCOLATOPSIS ORIENTALIS GENE EBH)/CN
E9 1 EPOTHILONE B N-OXIDE/CN
E10 1 EPOTHILONE B10/CN
E11 1 EPOTHILONE C/CN
E12 1 EPOTHILONE C BIS(TERT-BUTYLDIMETHYLSILYL) ETHER/CN
E13 1 EPOTHILONE C/D 12,13-EPOXIDASE/CN
E14 1 EPOTHILONE C/D MONOOXYGENASE/CN
E15 1 EPOTHILONE C/D SYNTHETASE/CN
E16 1 EPOTHILONE C1/CN
E17 1 EPOTHILONE C2/CN
E18 1 EPOTHILONE C3/CN
E19 1 EPOTHILONE C4/CN
E20 1 EPOTHILONE C5/CN
E21 1 EPOTHILONE C6/CN
E22 1 EPOTHILONE C7/CN
E23 1 EPOTHILONE C8/CN
E24 1 EPOTHILONE C9/CN
E25 1 EPOTHILONE D/CN


=> S E3
L1 1 "EPOTHILONE B"/CN

=> S L1 EXA SAM
SAMPLE IS IGNORED AS A SCOPE FOR THIS SEARCH
L2 1 "EPOTHILONE B"/CN

=> DIS L2 1 SAM
THE ESTIMATED COST FOR THIS REQUEST IS 1.04 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
IN 4,17-Dioxabicyclo[4.1.0]heptadecane-5,9-dione, 7,11-dihydroxy-
8,8,10,12,16-pentamethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-
, (1S,3S,7S,10R,11S,12S,16R)-
MF C27 H41 N O6 S

Absolute stereochemistry. Rotation (-).
Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	13.64	13.85

STN INTERNATIONAL LOGOFF AT 09:03:08 ON 07 JUL 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	29	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS	30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	31	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS	32	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS	33	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS EXPRESS		JUNE 27 08	CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* *

FILE 'HOME' ENTERED AT 10:09:50 ON 07 JUL 2008

=> file pctfull			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
FULL ESTIMATED COST	ENTRY	SESSION	
	0.21	0.21	

FILE 'PCTFULL' ENTERED AT 10:10:27 ON 07 JUL 2008
COPYRIGHT (C) 2008 Univentio

FILE LAST UPDATED: 4 JUL 2008 <20080704/UP>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW FIELD UPTX, FIELD /EW NO LONGER AVAILABLE - SEE HELP CHANGE <<<

=> s epothilon?
L1 2484 EPOTHILON?

=> s l1/ab or l1/ti
144 EPOTHILON?/AB
129 EPOTHILON?/TI
L2 159 (EPOTHILON?/AB) OR (EPOTHILON?/TI)

=> s l2 not py>2001
817323 PY>2001
L3 53 L2 NOT PY>2001

=> s combination and l3
567168 COMBINATION
264042 COMBINATIONS
617900 COMBINATION
(COMBINATION OR COMBINATIONS)
L4 33 COMBINATION AND L3

=> d ibib 1-5

L4 ANSWER 1 OF 33 PCTFULL COPYRIGHT 2008 Univentio on STN
ACCESSION NUMBER: 2001092255 PCTFULL ED 20020826
TITLE (ENGLISH): EPOTHILONE DERIVATIVES AND METHODS FOR MAKING
AND USING THE SAME
TITLE (FRENCH): DERIVES D'EPOTHILONE, PROCEDES DE PRODUCTION
ET METHODES D'UTILISATION
INVENTOR(S): SANTI, Daniel;
FARDIS, Maria;
ASHLEY, Gary
PATENT ASSIGNEE(S): KOSAN BIOSCIENCES, INC.;
SANTI, Daniel;
FARDIS, Maria;
ASHLEY, Gary
DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE
DESIGNATED STATES W:	WO 2001092255	A2	20011206
PRIORITY INFO.:	US 2000-60/207,655 US 2000-60/218,260 US 2000-60/231,552	20000526 20000714 20000911	
APPLICATION INFO.:	WO 2001-US15763	A	20010515
L4 ANSWER 2 OF 33	PCTFULL	COPYRIGHT 2008 Univentio on STN	
ACCESSION NUMBER:	2001083800	PCTFULL ED 20020826	
TITLE (ENGLISH):	PRODUCTION OF POLYKETIDES		
TITLE (FRENCH):	PRODUCTION DE POLYKETIDES		
INVENTOR(S):	ARSLANIAN, Robert, L.; ASHLEY, Gary; FRYKMAN, Scott; JULIEN, Bryan; KATZ, Leonard; KHOSLA, Chaitan; LAU, Janice; LICARDI, Peter, J.; REGENTIN, Rika; SANTI, Daniel; TANG, Li		
PATENT ASSIGNEE(S):	KOSAN BIOSCIENCES, INC.; ARSLANIAN, Robert, L.; ASHLEY, Gary; FRYKMAN, Scott; JULIEN, Bryan; KATZ, Leonard; KHOSLA, Chaitan; LAU, Janice; LICARDI, Peter, J.; REGENTIN, Rika; SANTI, Daniel; TANG, Li		
DOCUMENT TYPE:	Patent		
PATENT INFORMATION:	NUMBER	KIND	DATE
DESIGNATED STATES W:	WO 2001083800	A2	20011108
PRIORITY INFO.:	US 2000-09/560,367 US 2000-60/232,696 US 2000-60/257,517	20000428 20000914 20001221	

APPLICATION INFO.: US 2001-09/825,856 20010403
US 2001-09/825,876 20010403
US 2001-60/269,020 20010413
WO 2001-US13793 A 20010426

L4 ANSWER 3 OF 33 PCTFULL COPYRIGHT 2008 Univentio on STN
ACCESSION NUMBER: 2001081341 PCTFULL ED 20020826
TITLE (ENGLISH): 9-OXA-EPOTHILON DERIVATIVES, METHOD FOR THE
PRODUCTION AND USE THEREOF IN PHARMACEUTICAL
PREPARATIONS
TITLE (FRENCH): DERIVES DE 9-OXA-EPOTHILON, LEUR PROCEDE DE
PRODUCTION ET LEUR UTILISATION PHARMACEUTIQUE
INVENTOR(S): SCHWEDE, Wolfgang;
KLAR, Ulrich;
SKUBALLA, Werner;
BUCHMANN, Bernd;
HOFFMANN, Jens;
LICHTNER, Rosemarie
PATENT ASSIGNEE(S): SCHERING AKTIENGESELLSCHAFT;
SCHWEDE, Wolfgang;
KLAR, Ulrich;
SKUBALLA, Werner;
BUCHMANN, Bernd;
HOFFMANN, Jens;
LICHTNER, Rosemarie
DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE

WO 2001081341	A2	20011101

DESIGNATED STATES

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU
CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS
JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL
SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE
DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG
CI CM GA GN GW ML MR NE SN TD TG

PRIORITY INFO.: DE 2000-100 20 899.1 20000420
APPLICATION INFO.: WO 2001-EP4551 A 20010419

L4 ANSWER 4 OF 33 PCTFULL COPYRIGHT 2008 Univentio on STN
ACCESSION NUMBER: 2001073103 PCTFULL ED 20020822

TITLE (ENGLISH): PREPARATION OF EPOTHILON INTERMEDIATES
TITLE (FRENCH): PREPARATION D'INTERMEDIAIRES D'EPOTHILON

INVENTOR(S): VITE, Gregory, D.;
KIM, Soong-Hoon;
HOeEFLE, Gerhard

PATENT ASSIGNEE(S): BRISTOL-MYERS SQUIBB COMPANY;
VITE, Gregory, D.;
KIM, Soong-Hoon;
HOeEFLE, Gerhard

DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE

WO 2001073103	A2	20011004

DESIGNATED STATES

W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL
IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG

MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ
 TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ
 SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH
 CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ
 CF CG CI CM GA GN GW ML MR NE SN TD TG
 PRIORITY INFO.: US 2000-60/191,975 20000324
 APPLICATION INFO.: WO 2001-US9620 A 20010323

L4 ANSWER 5 OF 33 PCTFULL COPYRIGHT 2008 Univentio on STN
 ACCESSION NUMBER: 2001070716 PCTFULL ED 20020822
 TITLE (ENGLISH): A PROCESS FOR THE PREPARATION OF EPOTHILONE
 ANALOGS AND INTERMEDIATES
 TITLE (FRENCH): PREPARATION D'ANALOGUES ET D'INTERMEDIAIRES D'
 EPOTHILONE
 INVENTOR(S): LI, Wen, Sen;
 THORNTON, John, E.;
 GUO, Zhenrong;
 SWAMINATHAN, Shankar;
 MCCONLOGUE, Gary, W.
 PATENT ASSIGNEE(S): BRISTOL-MYERS SQUIBB COMPANY;
 LI, Wen, Sen;
 THORNTON, John, E.;
 GUO, Zhenrong;
 SWAMINATHAN, Shankar;
 MCCONLOGUE, Gary, W.
 DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
-----	-----	-----
WO 2001070716	A1	20010927

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR
 CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN
 IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK
 MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM
 TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW MZ SD
 SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY
 DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF
 CG CI CM GA GN GW ML MR NE SN TD TG

PRIORITY INFO.: US 2000-09/528,526 20000320
 APPLICATION INFO.: WO 2001-US7749 A 20010312

=> d his

(FILE 'HOME' ENTERED AT 10:09:50 ON 07 JUL 2008)

FILE 'PCTFULL' ENTERED AT 10:10:27 ON 07 JUL 2008
 L1 2484 S EPOTHILON?
 L2 159 S L1/AB OR L1/TI
 L3 53 S L2 NOT PY>2001
 L4 33 S COMBINATION AND L3

=> s l4 and (taxol or paclitaxel)
 9622 TAXOL
 272 TAXOLS
 9705 TAXOL
 (TAXOL OR TAXOLS)
 10390 PACLITAXEL
 72 PACLITAXELS
 10392 PACLITAXEL
 (PACLITAXEL OR PACLITAXELS)

L5 29 L4 AND (TAXOL OR PACLITAXEL)

=> s 15 and Her?

988529 HER?

L6 29 L5 AND HER?

=> s 15 and (HER2 or HER-2)

4722 HER2

118696 HER

1043 HER5

119313 HER

(HER OR HER5)

1276185 2

3260 HER-2

(HER(W) 2)

L7 1 L5 AND (HER2 OR HER-2)

=> d ibib abs

L7 ANSWER 1 OF 1 PCTFULL COPYRIGHT 2008 Univentio on STN

ACCESSION NUMBER: 1999002514 PCTFULL ED 20020515

TITLE (ENGLISH): EPOTHILONE DERIVATIVES

TITLE (FRENCH): DERIVES D'EPOTHILONE

INVENTOR(S): VITE, Gregory, D.;
BORZILLERI, Robert, M.;
KIM, Soong-Hoon;
JOHNSON, James, A.

PATENT ASSIGNEE(S): BRISTOL-MYERS SQUIBB COMPANY

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
WO 9902514	A2	19990121

DESIGNATED STATES

W:

AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC
LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM
KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE
CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
CF CG CI CM GA GN ML MR NE SN TD TG

PRIORITY INFO.: US 1997-60/051,951 19970708

US 1997-60/067,524 19971204

APPLICATION INFO.: WO 1998-US12550 A 19980616

ABEN The present invention relates to compounds of formula (I), Q is selected from the group consisting of (II), G is selected from the group consisting of alkyl, substituted alkyl, substituted or unsubstituted aryl, heterocyclo, (III), W is O or NR15; X is O or H, H; Y is selected from the group consisting of O; H, OR16; OR17, OR17; NOR18; H, NOR19; H, NR20R21; H, H; or CHR22; OR17OR17 can be a cyclic ketal; Z1 and Z2 are selected from the group consisting of CH2, O, NR23, S or SO2, wherein only one of Z and Z2 is a heteroatom; B1 and B2 are selected from the group consisting of OR24, or OCOR25, or 2CNR26R27; when B1 is H and Y is OH, H they can form a six-membered ring ketal or acetal; D is selected from the group consisting of NR28R29, NR30COR31 or saturated heterocycle R1, R2, R3, R4, R5, R6, R7, R13, R14, R18, R19, R20, R21, R22, R26 and R27 are

selected from the group H, alkyl, substituted alkyl, or aryl and when R1 and R2 are alkyl can be joined to form a cycloalkyl; R3 and R4 are alkyl can be joined to form a cycloalkyl; R9, R10, R16, R17, R24, R25, and R31 are selected from the group H, alkyl, or substituted alkyl; R8, R11, R12, R28, R30, R32, R33, and R30 are selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, or heterocyclo; R15, R23 and R29 are selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, heterocyclo, R32C=O, R33SO₂, hydroxy, O-alkyl or O-substituted alkyl, the pharmaceutically acceptable salts thereof and any hydrates, solvates or geometric, optical and stereoisomers thereof, with the proviso that compounds wherein: W and X are both O; and R1, R2, R7 are H; and R3, R4, R6, are methyl; and R8, is H or methyl; and Z1, and Z2, are CH₂; and G is 1-methyl-2-(substituted-4-thiazolyl)ethenyl; and Q is as defined above are excluded.

ABFR La presente invention concerne des composes de la formule (I) dans laquelle Q est selectionne dans le groupe constitue par le groupement (II); G est selectionne dans le groupe constitue par alkyle, akyle substitue, aryle substitue ou insusbstitue, heterocyclo, le groupement (III); W est O ou NR15; X est O ou H, H; Y est selectionne dans le groupe constitue par O; H, OR16; OR17, OR17; NOR18; H, NOR19; H, NR20R21; H, H; ou CHR22; OR17, OR17 pouvant etre un cetal cyclique; Z1 et Z2 sont selectionnes dans le groupe constitue par CH₂, O, NR23, S ou SO₂, dans lequel seuls Z et Z2 sont un heteroatome; B1 et B2 sont selectionnes dans le groupe constitue par OR24 ou OCOR25 ou O2CNR26R27; et peuvent former ensemble un noyau cetal ou acetal a six chainons si B1 est H et Y est OH, H; D est selectionne dans le groupe constitue par NR28R29, NR30COR31 ou un heterocycle sature. R1, R2, R3, R4, R5, R6, R7, R13, R14, R18, R19, R20, R21, R22, R26 et R27 sont selectionnes dans le groupe constitue par H, alkyle, alkyle substitue ou aryle, et peuvent former ensemble un cycloalkyle si R1 et R2 ou R3 et R4 sont alkyle; R9, R10, R16, R17, R24, R25 et R31 sont selectionnes dans le groupe constitue par H, alkyle ou alkyle substitue; R8, R11, R12, R28, R30, R32, R33 et R30 sont selectionnes dans le groupe constitue par H, alkyle, alkyle substitue, aryle, aryle substitue, cycloalkyle ou heterocyclo; R15, R23 et R29 sont selectionnes dans le groupe constitue par H, alkyle, alkyle substitue, aryle, aryle substitue, cycloalkyle ou heterocyclo, R32C=O, R33SO₂, hydroxy, O-alkyle ou O-alkyle substitue, leurs sels pharmaceutiquement acceptables ou leurs eventuels hydrates, solvates ou isomeres geometriques, optiques, ou stereoisomeres, a condition que soient exclus les composes dans lesquels W et X sont tous deux O; et R1, R2 et R7 sont H; et R3, R4 et R6 sont methyle; et R8 est H ou methyle; et Z1 et Z2 sont CH₂; et G est

1-methyl-2-(substitue-4-thiazolyl)ethenyle; et Q est tel que defini ci-dessus.

=> d his

(FILE 'HOME' ENTERED AT 10:09:50 ON 07 JUL 2008)

FILE 'PCTFULL' ENTERED AT 10:10:27 ON 07 JUL 2008

L1 2484 S EPOTHILON?
L2 159 S L1/AB OR L1/TI
L3 53 S L2 NOT PY>2001
L4 33 S COMBINATION AND L3
L5 29 S L4 AND (TAXOL OR PACLITAXEL)
L6 29 S L5 AND HER?
L7 1 S L5 AND (HER2 OR HER-2)

=> s 16 and (HER2 or HER-2)

4722 HER2
118696 HER
1043 HER
119313 HER
 (HER OR HERs)
1276185 2
3260 HER-2
 (HER(W) 2)
L8 1 L6 AND (HER2 OR HER-2)

=> s 15 and (HER2 or HER-2)

4722 HER2
118696 HER
1043 HER
119313 HER
 (HER OR HERs)
1276185 2
3260 HER-2
 (HER(W) 2)
L9 1 L5 AND (HER2 OR HER-2)

=> d ibib abs kwic

L9 ANSWER 1 OF 1 PCTFULL COPYRIGHT 2008 Univentio on STN

ACCESSION NUMBER: 1999002514 PCTFULL ED 20020515

TITLE (ENGLISH): EPOTHILONE DERIVATIVES

TITLE (FRENCH): DERIVES D'EPOTHILONE

INVENTOR(S): VITE, Gregory, D.;
 BORZILLERI, Robert, M.;
 KIM, Soong-Hoon;
 JOHNSON, James, A.

PATENT ASSIGNEE(S): BRISTOL-MYERS SQUIBB COMPANY

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

	NUMBER	KIND	DATE

	WO 9902514	A2	19990121

DESIGNATED STATES

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE
 ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC
 LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU
 SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW GH GM
 KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE

CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ
CF CG CI CM GA GN ML MR NE SN TD TG
PRIORITY INFO.: US 1997-60/051,951 19970708
US 1997-60/067,524 19971204

APPLICATION INFO.: WO 1998-US12550 A 19980616

ABEN The present invention relates to compounds of formula (I), Q is selected from the group consisting of (II), G is selected from the group consisting of alkyl, substituted alkyl, substituted or unsubstituted aryl, heterocyclo, (III), W is O or NR15; X is O or H,H; Y is selected from the group consisting of O; H,OR16; OR17,OR17; NOR18; H,NOR19; H,NR20R21; H,H; or CHR22; OR17OR17 can be a cyclic ketal; Z1 and Z2 are selected from the group consisting of CH2, O, NR23, S or SO2, wherein only one of Z and Z2 is a heteroatom; B1 and B2 are selected from the group consisting of OR24, or OCOR25, or 2CNR26R27; when B1 is H and Y is OH, H they can form a six-membered ring ketal or acetal; D is selected from the group consisting of NR28R29, NR30COR31 or saturated heterocycle R1, R2, R3, R4, R5, R6, R7, R13, R14, R18, R19, R20, R21, R22, R26 and R27 are selected from the group H, alkyl, substituted alkyl, or aryl and when R1 and R2 are alkyl can be joined to form a cycloalkyl; R3 and R4 are alkyl can be joined to form a cycloalkyl; R9, R10, R16, R17, R24, R25, and R31 are selected from the group H, alkyl, or substituted alkyl; R8, R11, R12, R28, R30, R32, R33, and R30 are selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, or heterocyclo; R15, R23 and R29 are selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, heterocyclo, R32C=O, R33SO2, hydroxy, O-alkyl or O-substituted alkyl, the pharmaceutically acceptable salts thereof and any hydrates, solvates or geometric, optical and stereoisomers thereof, with the proviso that compounds wherein: W and X are both O; and R1, R2, R7 are H; and R3, R4, R6, are methyl; and R8, is H or methyl; and Z1, and Z2, are CH2; and G is 1-methyl-2-(substituted-4-thiazolyl)ethenyl; and Q is as defined above are excluded.

ABFR La presente invention concerne des composes de la formule (I) dans laquelle Q est selectionne dans le groupe constitue par le groupement (II); G est selectionne dans le groupe constitue par alkyle, akyle substitue, aryle substitue ou insusbstite, heterocyclo, le groupement (III); W est O ou NR15; X est O ou H,H; Y est selectionne dans le groupe constitue par O; H,OR16; OR17,OR17; NOR18; H,NOR19; H,NR20R21; H,H; ou CHR22; OR17,OR17 pouvant etre un cetal cyclique; Z1 et Z2 sont selectionnes dans le groupe constitue par CH2, O, NR23, S ou SO2, dans lequel seuls Z et Z2 sont un heteroatome; B1 et B2 sont selectionnes dans le groupe constitue par OR24 ou OCOR25 ou 2CNR26R27; et peuvent former ensemble un noyau cetal ou acetal a six chainons si B1 est H et Y est OH,H; D est selectionne dans le groupe constitue par NR28R29, NR30COR31 ou un heterocycle sature. R1, R2, R3,

R4, R5, R6, R7, R13, R14, R18, R19, R20, R21, R22, R26 et R27 sont selectionnes dans le groupe constitue par H, alkyle, alkyle substitue ou aryle, et peuvent former ensemble un cycloalkyle si R1 et R2 ou R3 et R4 sont alkyle; R9, R10, R16, R17, R24, R25 et R31 sont selectionnes dans le groupe constitue par H, alkyle ou alkyle substitue; R8, R11, R12, R28, R30, R32, R33 et R30 sont selectionnes dans le groupe constitue par H, alkyle, alkyle substitue, aryle, aryle substitue, cycloalkyle ou heterocyclo; R15, R23 et R29 sont selectionnes dans le groupe constitue par H, alkyle, alkyle substitue, aryle, aryle substitue, cycloalkyle ou heterocyclo, R32C=O, R33SO₂, hydroxy, O-alkyle ou O-alkyle substitue, leurs sels pharmaceutiquement acceptables ou leurs eventuels hydrates, solvates ou isomeres geometriques, optiques, ou stereoisomeres, a condition que soient exclus les composes dans lesquels W et X sont tous deux O; et R1, R2 et R7 sont H; et R3, R4 et R6 sont methyle; et R8 est H ou methyle; et Z1 et Z2 sont CH₂; et G est 1-methyl-2-(substitue-4-thiazolyl)ethenyle; et Q est tel que defini ci-dessus.

TIEN EPOTHILONE DERIVATIVES
TIFR DERIVES D'EPOTHILONE

DETD R
S Me
jOH
N3] ,]'] '
O Me
O OH O
I EpothiloneA R=H
II EpothiloneB R=Me
have been found to exert microtubule-stabilizing effects similar to TAXOL and hence cytotoxic activity against rapidly proliferating'cells, such as, tumor cells or other hyperproliferative cellular disease, see .Angew. Chem. Int. Ed. Engl.,.. . .

The compounds of this invention. are also useful in combination with known anti-cancer and cytotoxic agents and treatments, including radiation. If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent within its approved dosage range. Compounds of formula V can be used sequentially with known anticancer or cytotoxic agents and treatment, including radiation when a combination formulation is inappropriate.

Especially useful are cytotoxic drug combinations wherein the second drug chosen acts in a different phase of the cell cycle, e.g. S phase, than the present compounds of. . .

. . .
Synthase Inhibitors,
DNA Cross Linking Agents
Topoisomerase I and II Inhibitors
DNA Alkylating Agents

Ribonucleoside Reductase Inhibitors
Cytotoxic Factors e.g. TNF-alpha or
Growth factor inhibitors e.g. HER 2 receptor MAB's
The present compounds may exist as multiple optical, geometric,
and stereoisomers. Included within the present invention are all such
isomers and. . .
. . .
potency is
accomplished following a modified procedure of Swindell, et al., (see
Swindell, C.S., Krauss, N.E., Horwitz, S.B., and Ringel, I. Biologically
active taxol analogues with deleted A-ring side chain
substituents and
variable C-2' configurations. J. Med. Chem. 34: 1176-1184, 1991). These
modifications, in part, result. . .
. . .
cells were incubated at 37° for 72 hours at which time the
tetrazolium dye, MTS at 333 gg/ml (final concentration), in
combination
with the electron coupling agent phenazine methosulfate at 25 gm (final
concentration) was added. A dehydrogenase enzyme in live cells
reduces the MTS. . .

=>

--Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	23.30	23.51

STN INTERNATIONAL LOGOFF AT 10:14:45 ON 07 JUL 2008